Clinical Trial Search

Primary: Change From Baseline to 6 Month Endpoint in Child Health and Illness Profile - Child Edition, Parent Report Form (CHIP-CE PRF), Achievement Domain — 28.0; 28.3; 8.4…

Primary: Sustained Freedom From Migraine Pain Between 2-24 Hours Post-dose — 10; 41 Participants — p=<0.001

Primary: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 — -0.85; -0.15 Percent — p=<0.001

Primary: Number of Participants Who Experienced an Adverse Event — 32; 25 Participants

Primary: Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Total Score — -8.6; -8.8; -3.8 units on a scale

Primary: Height Velocity From Pretreatment (Week 0) to Week 34 — 7.0 centimeters per year (cm/yr)

Primary: Hemoglobin A1c (HbA1c) Change From Baseline to Week 18 — 7.68; 7.69; 7.16; 7.07 Percent

Primary: Risk of Experiencing a Primary Outcome Event (POE) (i.e., Nonfatal Myocardial Infarction [MI], Nonfatal Stroke, Resuscitated Cardiac Arrest, Cardiovascular [CV] Death)…

Primary: Change From Baseline at Week 12 in Average Pain Severity Rating Using Diaries for the Combined Duloxetine Arms (40 mg + 60 mg) — -1.61; -2.47 units on a scale — p=<0.0001

Primary: Change in Systolic Blood Pressure From Baseline to Week 12 — -19.9; -20.8 mm Hg — p=0.395

Primary: Change in Early Morning UPDRS Part III Score — -7.0; -3.9 units on a scale — p=0.0002

Primary: Mean Intraocular Pressure — 16.5 millimeters mercury (mm Hg)

Primary: Participants With Neurologic Impairment at 12 Months as Measured by a Bayley's Neuro-developmental Assessment (Motor Scores). — 10; 5; 0; 1 participants

Primary: Participants With Neurologic Impairment at 12 Months as Measured by a Bayley's Neuro-developmental Assessment.(Motor Scores) — 0; 3; 0; 0 Participants

Primary: Number of Participants With Healing of Reflux Esophagitis (RE) Who Were Graded "O" at Week 8 Out of Patients Who Were Graded "A, B, C or D" at Baseline According to Los…